AVITA MEDICAL INC (RCEL)
US05380C1027 - Common Stock
AVITA Medical Announces FDA Approval of RECELL GO mini, Optimizing Treatment for Smaller Wounds
AVITA Medical Announces FDA Approval of RECELL GO mini, Optimizing Treatment for Smaller Wounds
AVITA Medical receives FDA approval for RECELL GO mini, optimizing treatment for smaller wounds and expanding patient accessibility....
AVITA Medical Announces FDA 510(k) Clearance for Cohealyx, Expanding its Addressable Market
AVITA Medical Announces FDA 510(k) Clearance for Cohealyx, Expanding its Addressable Market
AVITA Medical announces FDA clearance for Cohealyx, a new collagen-based dermal matrix, expanding its addressable market....
AVITA Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference
AVITA Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference
AVITA Medical to present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025, at 9:00 a.m. Pacific Time....
AVITA Medical to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference
AVITA Medical to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference
VALENCIA, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company...
AVITA Medical Announces Exclusive Distribution Agreement to Expand to Australia and New Zealand
AVITA Medical Announces Exclusive Distribution Agreement to Expand to Australia and New Zealand
AVITA Medical announces exclusive distribution agreement to expand the RECELL product platform to Australia and New Zealand....
AVITA Medical to Host Investor Webinar Briefing
AVITA Medical to Host Investor Webinar Briefing
AVITA Medical invites shareholders and prospective investors to attend its investor webinar briefing and presentation on November 12, 2024....
AVITA Medical Reports Third Quarter Financial Results
AVITA Medical Reports Third Quarter Financial Results
AVITA Medical reported third-quarter commercial revenue of $19.5 million, reflecting an approximately 44% increase over the same period last year....
AVITA Medical to Announce Third Quarter 2024 Financial Results
AVITA Medical to Announce Third Quarter 2024 Financial Results
AVITA Medical announced that it will report its third quarter 2024 financial results after the close of the U.S. financial markets on November 7, 2024....
AVITA Medical to Present at 2024 Cantor Global Healthcare Conference
AVITA Medical to Present at 2024 Cantor Global Healthcare Conference
AVITA Medical to present at the 2024 Cantor Global Healthcare Conference on September 18, 2024, at 9:10 a.m. Eastern Time....
AVITA Medical to Participate in Lake Street’s 8th Annual Best Ideas Growth (BIG8) Conference
AVITA Medical to Participate in Lake Street’s 8th Annual Best Ideas Growth (BIG8) Conference
AVITA Medical will participate in Lake Street Capital Markets’ 8th Annual Best Ideas Growth (BIG8) Conference in New York on September 12, 2024....
RCEL Stock Earnings: AVITA Medical Misses EPS, Beats Revenue for Q2 2024
RCEL stock results show that AVITA Medical missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
RCEL Stock Earnings: AVITA Medical Misses EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips AVITA Medical (NASDAQ:RCEL) just reported results for the second quarter of 202...
AVITA Medical to Host Investor Webinar Briefing
AVITA Medical to Host Investor Webinar Briefing
AVITA Medical invites shareholders and prospective investors to attend its investor webinar briefing and presentation on August 13, 2024....
AVITA Medical Reports Second Quarter Financial Results
AVITA Medical Reports Second Quarter Financial Results
AVITA Medical today reported second-quarter commercial revenue of $15.1 million, reflecting growth of over 29% over the same period in the prior year. ...
AVITA Medical Names Robin VanDenburgh as SVP of U.S. Commercial Sales
AVITA Medical Expands Portfolio with Unique Dermal Matrix to Advance Wound Care
Exclusive development and distribution agreement with Regenity Biosciences provides AVITA Medical with the commercialization rights to a unique collagen-based dermal matrix following 510(k) clearance
AVITA Medical to Announce Second Quarter 2024 Financial Results
AVITA Medical to Announce Second Quarter 2024 Financial Results
AVITA Medical will report its second quarter 2024 financial results after market close on August 8 2024 and host a webcast that day at 1:30 PM PDT....
AVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary
Donna Shiroma retires after distinguished service as General Counsel
AVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary
AVITA Medical appoints Nicole Kelsey as Chief Legal and Compliance Officer and Corporate Secretary, succeeding Donna Shiroma who is retiring as GC....
AVITA Medical Achieves Milestone with First Case Using RECELL GO
Joseph M. Still Burn Center at Doctors Hospital of Augusta first to treat a patient using AVITA Medical’s FDA-Approved RECELL GO System for thermal burn wounds and full-thickness skin defects
AVITA Medical Achieves Milestone with First Case Using RECELL GO
Joseph M. Still Burn Center at Doctors Hospital of Augusta treats first patient using AVITA Medical’s FDA-Approved RECELL GO System....
Commit To Buy AVITA Medical At $7.50, Earn 81.1% Annualized Using Options
AVITA Medical Announces FDA Approval of RECELL GO
AVITA Medical Announces FDA Approval of RECELL GO
AVITA Medical receives FDA approval for RECELL GO, its next-generation device used to treat thermal burn wounds and full thickness skin defects....
AVITA Medical to Host Investor Webinar Briefing
AVITA Medical to Host Investor Webinar Briefing
AVITA Medical to host investor webinar briefing and presentation on May 21, 2024, at 4:00 p.m. Pacific Daylight Time....